Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis-Reference-Cited by-同舟云学术

Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis

Published:2023-05 Issue:3 Volume:10 Page:
ISSN:2332-7812
Container-title:Neurology Neuroimmunology & Neuroinflammation
language:en
Short-container-title:Neurol Neuroimmunol Neuroinflamm

Author:

Garcia Alexandra¹^ORCID,Dugast Emilie¹^ORCID,Shah Sita¹^ORCID,Morille Jérémy¹,Lebrun-Frenay Christine¹^ORCID,Thouvenot Eric¹^ORCID,De Sèze Jérôme¹,Le Page Emmanuelle¹,Vukusic Sandra¹,Maurousset Aude¹,Berger Eric¹,Casez Olivier¹,Labauge Pierre¹,Ruet Aurélie¹,Raposo Catarina¹,Bakdache Fabien¹^ORCID,Buffels Régine¹,Le Frère Fabienne¹,Nicot Arnaud¹^ORCID,Wiertlewski Sandrine¹,Gourraud Pierre-Antoine¹^ORCID,Berthelot Laureline¹,Laplaud David¹^ORCID

Affiliation:

1. From the CHU Nantes (A.G., E.D., S.S., J.M., A.N., S.W., P.-A.G., L.B., D.L.), Nantes Université, INSERM UMR1064, Center for Research in Transplantation and Translational Immunology (CR2TI); CRCSEP (C.L.-F.), CHU de Nice Pasteur 2, Université Nice Côte d'Azur UR2CA URRIS; Service de Neurologie (E.T.), CHU de Nîmes, Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM; Service de Neurologie et Centre d'Investigation Clinique (J.D.S.), CHU de Strasbourg; Service de Neurologie ...

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical),Neurology

Link

https://www.neurology.org/doi/pdfdirect/10.1212/NXI.0000000000200091

Reference32 articles.

1. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

2. Ofatumumab versus Teriflunomide in Multiple Sclerosis

3. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis

4. Reciprocal regulation of polarized cytokine production by effector B and T cells

5. The who, how and where of antigen presentation to B cells

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8 ⁺ T-Cell Proliferation in Patients With Multiple Sclerosis;Neurology Neuroimmunology & Neuroinflammation;2024-07

2. Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MS;Frontiers in Neurology;2024-04-16

3. Alterations in the innate and adaptive immune system in a real-world cohort of multiple sclerosis patients treated with ocrelizumab;Clinical Immunology;2024-02

4. Repeated iv anti‐CD20 treatment in multiple sclerosis: Long‐term effects on peripheral immune cell subsets;Annals of Clinical and Translational Neurology;2024-01-10

5. Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis;Journal of Neuroinflammation;2023-09-26